Traders Sell Gilead Sciences, Inc. (GILD) on Strength (GILD)

Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Tuesday. $73.22 million flowed into the stock on the tick-up and $133.00 million flowed out of the stock on the tick-down, for a money net flow of $59.78 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.38 for the day and closed at $72.51

GILD has been the subject of a number of recent analyst reports. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target for the company. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $84.87.

The company has a market cap of $94,717.57, a P/E ratio of 7.57, a PEG ratio of -1.21 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.75 earnings per share. research analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at $8,945,723. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 666,819 shares of company stock worth $52,303,086. 1.30% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Welch Investments LLC bought a new position in shares of Gilead Sciences in the third quarter valued at $108,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Penserra Capital Management LLC lifted its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences in the third quarter valued at $133,000. Finally, American Beacon Advisors Inc. bought a new position in shares of Gilead Sciences in the first quarter valued at $143,000. 76.30% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2017/11/23/traders-sell-gilead-sciences-inc-gild-on-strength-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply